Skip to Content

Gadobutrol Pregnancy and Breastfeeding Warnings

Gadobutrol is also known as: Gadavist

Gadobutrol Pregnancy Warnings

Animal studies have shown evidence of embryolethality. There are no controlled data in human pregnancy. AU TGA pregnancy category B3: Drugs which have been taken by only a limited number of pregnant women and women of childbearing age, without an increase in the frequency of malformation or other direct or indirect harmful effects on the human fetus having been observed. Studies in animals have shown evidence of an increased occurrence of fetal damage, the significance of which is considered uncertain in humans. US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

This drug should be used only if clearly needed and the benefit outweighs the risk to the fetus. AU TGA pregnancy category B3 US FDA pregnancy category C

See references

Gadobutrol Breastfeeding Warnings

US: Safety has not been established. May consider interrupting breastfeeding and pumping and discarding breast milk up to 18 hours post-drug administration to minimize exposure to infant. UK: May consider continuing or discontinuing breastfeeding for 24 hours after administration of the drug. AU: At clinical doses, no effects on the infant are anticipated and this drug can be used during breastfeeding. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant are unknown.

Reports on the use of other gadolinium-based contrast agents have shown 0.01% to 0.04% of the maternal gadolinium dose is present in breast milk with limited gastrointestinal absorption in the infant. In lactating rats receiving 0.5 mmol/kg of IV [153Gd]-gadobutrol, 0.01% of the total administered radioactivity was transferred to the offspring via milk within 3 hours after administration.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "Australian Product Information." O 0
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Gadavist (gadobutrol)." Bayer Pharmaceutical Inc, West Haven, CT.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  4. "Product Information. Gadavist (gadobutrol)." Bayer Pharmaceutical Inc, West Haven, CT.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.